Clinical trials: Cancer of Brain
Adult Intracranial Tumor, Adult Solid Tumor
A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain
This will be a randomized blinded clinical trial. Patients will be randomized to receive either a remifentanil or dexmedetomidine infusion for general anesthesia.
- Trial name
- RemivsDex (NCT01269918)
- Testing
- Remifentanil, Dexmedetomidine
- Where
- 2 sites in United States
- Volunteers
- 142 people
- Sponsor
- The Cleveland Clinic
Breast Cancer
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain.
- Trial name
- NCT01494662
- Testing
- HKI-272, Surgical Resection, Capecitabine
- Where
- 18 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Glioma, Medulloblastoma
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.
- Trial name
- NCT00404495
- Testing
- Irinotecan, Temozolomide
- Where
- 29 sites in Australia, Belgium and 6 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
HER-2 Positive Breast Cancer
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with human…
- Trial name
- NCT01305941
- Testing
- Everolimus, Vinorelbine, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
RATIONALE: Acupressure wristbands may prevent or reduce nausea and caused by chemotherapy. It is not yet known whether standard care is more effective with or without acupressure wristbands in controlling acute and delayed…
- Conditions
- Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- SCUSF1202 (NCT01346267)
- Testing
- Real Acupressure Band
- Where
- 25 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- University of South Florida
Brain Metastases
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).
- Trial name
- NCT02031237
- Testing
- Single Fraction Stereotactic Radiosurgery (SRS), Fractionated Whole Brain Radiation Therapy (WBRT), Fractionated Stereotactic Radiation Therapy (FSRT)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Michigan Rogel Cancer Center
Gonadotroph Adenomas
Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone…
- Trial name
- LAR (NCT00929669)
- Testing
- pasireotide LAR
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Glioblastoma, Brain Tumor, Recurrent
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
This multicenter, 2-stage, open-label, phase II trial aims to assess the efficacy and safety of dacomitinib in adult patients with recurrent Glioblastoma (GBM) with EGFR gene amplification and/or EGFRvIII mutation.
- Trial name
- NCT01520870
- Testing
- PF-299804 (Dacomitinib)
- Where
- 12 sites in Spain
- Volunteers
- 49 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Breast Cancer, Fatigue
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors…
- Conditions
- Breast Cancer, Fatigue, Sleep Disorders
- Trial name
- Co-SOFT (NCT00659373)
- Testing
- Tamoxifen, triptorelin, Exemestane
- Where
- 15 sites in United States, Canada
- Volunteers
- 86 people
- Sponsor
- ETOP IBCSG Partners Foundation
Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation…
- Conditions
- Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm
- Trial name
- NCT00049127
- Testing
- Imatinib Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 229 sites in United States
- Volunteers
- 64 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Glioblastoma, Gliosarcoma
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form.
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00667394
- Testing
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, Brain Cancer
Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy
The aim of this protocol is to refine the accuracy of proton beam therapy (PT) by the use of dual energy computed tomography (DECT), in conjunction with novel iterative image reconstruction algorithms, to more precisely determine…
- Conditions
- Lung Cancer, Brain Cancer, Head and Neck Cancer
- Trial name
- NCT03403361
- Testing
- Siemens Somatom Definition Edge, Philips Brilliance Big Bore CT/simulator
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Glioblastoma Multiforme
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00892177
- Testing
- bevacizumab, dasatinib
- Where
- 305 sites in United States
- Volunteers
- 144 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain and Central Nervous System Tumors
Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Phase I/II trial to estimate the maximum tolerated dose of imatinib mesylate in newly diagnosed brain stem gliomas and recurrent high grade gliomas and to assess the effectiveness of imatinib mesylate in treating young patients…
- Trial name
- NCT00021229
- Testing
- imatinib mesylate, local irradiation therapy
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Central Nervous System Tumor
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00085098
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group
Melanoma, Metastatic Melanoma
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread…
- Trial name
- NCT04899921
- Testing
- Ipilimumab, Nivolumab, Troriluzole
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma and Brain Metastases
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain.
- Trial name
- NCT02039947
- Testing
- Dabrafenib, Trametinib
- Where
- 47 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiosurgery before surgery may make the tumor smaller and reduce the amount of…
- Trial name
- NCT00811655
- Testing
- therapeutic conventional surgery, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University